# Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

> **NCT02499146** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 26 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT02499146
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-11
- **Primary completion:** 2018-07-31
- **Final completion:** 2024-12-24
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02499146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02499146, "Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02499146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*